Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 4Phase 1 3Phase NA 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Unknown 3Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Unknown × aumolertinib × Clear all
NCT05826483 2023-04-24

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Guangzhou Institute of Respiratory Disease

Phase 1 Unknown
20 enrolled
Thoracic

Lung Neoplasms

NCT05430386 2023-02-14

Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Unknown
174 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05223595 2022-02-04

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
42 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡